Evotec SE (MIL:1EVT) Accounts Payable & Accrued Expense : €70.5 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Evotec SE Accounts Payable & Accrued Expense?

Evotec SE's quarterly accounts payable & accrued expense increased from Sep. 2024 (€73.7 Mil) to Dec. 2024 (€99.8 Mil) but then declined from Dec. 2024 (€99.8 Mil) to Mar. 2025 (€70.5 Mil).

Evotec SE's annual accounts payable & accrued expense increased from Dec. 2022 (€108.1 Mil) to Dec. 2023 (€142.7 Mil) but then declined from Dec. 2023 (€142.7 Mil) to Dec. 2024 (€99.8 Mil).

Evotec SE Accounts Payable & Accrued Expense Historical Data

The historical data trend for Evotec SE's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Accounts Payable & Accrued Expense Chart

Evotec SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

45.91

83.19

108.12

142.68

99.77

Evotec SE Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															105.00	95.34	73.68	99.77	70.47

Evotec SE Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Evotec SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (MIL:1EVT) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

EVO:USA EVTd:UK 0IRF:UK EVT:Germany EVT:Bulgaria EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE Headlines

No Headlines